Abstract
Platensimycin (PTM) and platencin (PTN), isolated from several strains of Streptomyces platensis are potent antibiotics against multi-drug resistant bacteria. PTM was also shown to have antidiabetic and antisteatotic activities in mouse models. Through a novel genome-mining method, we have recently identified six PTM and PTN dual-producing strains, and generated several mutants with improved production of PTM or PTN by inactivating the pathway-specific transcriptional repressor gene ptmR1. Among them, S. platensis SB12026 gave the highest titer of 310 mg/L for PTM. In this study, we now report titer improvement by medium and fermentation optimization and pilot-scale production and isolation of PTM from SB12026. The fermentation medium optimization was achieved by manipulating the carbon and nitrogen sources, as well as the inorganic salts. The highest titer of 1560 mg/L PTM was obtained in 15-L fermentors, using a formulated medium mainly containing soluble starch, soybean flour, morpholinepropanesulfonic acid sodium salt and CaCO3. In addition, a polyamide chromatographic step was applied to facilitate the purification and 45.14 g of PTM was successfully obtained from a 60 L scale fermentation. These results would speed up the future development of PTM as human medicine.
Similar content being viewed by others
References
Aluotto S, Tynan H, Maggio C, Falzone M, Mukherjee A, Gullo V, Demain AL (2013) Development of a semi-defined medium supporting production of platensimycin and platencin by Streptomyces platensis. J Antibiot 66:51–54
Brown AK, Taylor RC, Bhatt A, Futterer K, Besra GS (2009) Platensimycin activity against mycobacterial β-ketoacyl-ACP synthases. PLoS One 4:e6306
Cragg GM, Grothaus PG, Newman DJ (2014) New horizons for old drugs and drug leads. J Nat Prod 77(3):703–723
Falzone M, Martens E, Tynan H, Maggio C, Golden S, Nayda V, Crespo E, Inamine G, Gelber M, Lemence R, Chiappini N, Friedman E, Shen B, Gullo V, Demain AL (2013) Development of a chemically defined medium for the production of the antibiotic platensimycin by Streptomyces platensis. Appl Microbiol Biotechnol 97:9535–9539
Hara M, Asano K, Kawamoto I, Takiguchi T, Katsumata S, Takahashi K, Nakano H (1989) Leinamycin, a new antitumor antibiotic from Streptomyces: producing organism, fermentation and isolation. J Antibiot 42:1768–1774
Herath KB, Zhang C, Jayasuriya H, Ondeyka JG, Zink DL, Burgess B, Wang J, Singh SB (2008) Structure and semisynthesis of platensimide A, produced by Streptomyces platensis. Org Lett 10:1699–1702
Hindra Huang T, Yang D, Rudolf JD, Xie P, Xie G, Teng Q, Lohman JR, Zhu X, Huang Y, Zhao LX, Jiang Y, Duan Y, Shen B (2014) Strain prioritization for natural product discovery by a high-throughput real-time PCR method. J Nat Prod 77:2296–2303
International Diabetes Federation (2015) IDF Diabetes, 7 ed. International Diabetes Federation, Brussels. http://www.diabetesatlas.org. Accessed 1 Feb 2016
Jayasuriya H, Herath KB, Zhang C, Zink DL, Basilio A, Genilloud O, Diez MT, Vicente F, Gonzalez I, Salazar O, Pelaez F, Cummings R, Ha S, Wang J, Singh SB (2007) Isolation and structure of platencin: a FabH and FabF dual inhibitor with potent broad-spectrum antibiotic activity. Angew Chem Int Ed Engl 46:4684–4688
Kieser T, Bibb MJ, Buttner MJ, Chater KF, Hopwood DA (2000) Practical Streptomyces genetics. The John Innes Foundation, Norwich
Martens E, Demain AL (2011) Platensimycin and platencin: promising antibiotics for future application in human medicine. J Antibiot 64:705–710
Newman DJ, Cragg GM (2012) Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 75:311–335
Nicolaou KC, Edmonds DJ, Li A, Tria GS (2007) Asymmetric total syntheses of platensimycin. Angew Chem Int Ed Engl 46:3942–3945
Rudolf JD, Dong LB, Huang T, Shen B (2015) A genetically amenable platensimycin- and platencin-overproducer as a platform for biosynthetic explorations: a showcase of PtmO4, a long-chain acyl-CoA dehydrogenase. Mol BioSyst 11:2717–2726
Shen HC, Ding FX, Singh SB, Parthasarathy G, Soisson SM, Ha SN, Chen X, Kodali S, Wang J, Dorso K, Tata JR, Hammond ML, Maccoss M, Colletti SL (2009) Synthesis and biological evaluation of platensimycin analogs. Bioorg Med Chem Lett 19:1623–1627
Singh SB, Jayasuriya H, Ondeyka JG, Herath KB, Zhang C, Zink DL, Tsou NN, Ball RG, Basilio A, Genilloud O, Diez MT, Vicente F, Pelaez F, Young K, Wang J (2006) Isolation, structure, and absolute stereochemistry of platensimycin, a broad spectrum antibiotic discovered using an antisense differential sensitivity strategy. J Am Chem Soc 128:11916–11920
Smanski MJ, Peterson RM, Rajski SR, Shen B (2009) Engineered Streptomyces platensis strains that overproduce antibiotics platensimycin and platencin. Antimicrob Agents Chem 53:1299–1304
Spizek J, Novotna J, Rezanka T, Demain AL (2010) Do we need new antibiotics? The search for new targets and new compounds. J Ind Microbiol Biotechnol 37:1241–1248
Walsh CT, Wencewicz TA (2014) Prospects for new antibiotics: a molecule-centered perspective. J Antibiot 67:7–22
Wang J, Soisson SM, Young K, Shoop W, Kodali S, Galgoci A, Painter R, Parthasarathy G, Tang YS, Cummings R, Ha S, Dorso K, Motyl M, Jayasuriya H, Ondeyka J, Herath K, Zhang C, Hernandez L, Allocco J, Basilio A, Tormo JR, Genilloud O, Vicente F, Pelaez F, Colwell L, Lee SH, Michael B, Felcetto T, Gill C, Silver LL, Hermes JD, Bartizal K, Barrett J, Schmatz D, Becker JW, Cully D, Singh SB (2006) Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 441:358–361
Wang J, Kodali S, Lee SH, Galgoci A, Painter R, Dorso K, Racine F, Motyl M, Hernandez L, Tinney E, Colletti SL, Herath K, Cummings R, Salazar O, González I, Basilio A, Vicente F, Genilloud O, Pelaez F, Jayasuriya H, Young K, Cully DF, Singh SB (2007) Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties. Proc Natl Acad Sci USA 104:7612–7616
Wu M, Singh SB, Wang J, Chung CC, Salituro G, Karanam BV, Lee SH, Powles M, Ellsworth KP, Lassman ME, Miller C, Myers RW, Tota MR, Zhang BB, Li C (2011) Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes. Proc Natl Acad Sci USA 108:5378–5383
Yu Z, Smanski MJ, Peterson RM, Marchillo K, Andes D, Rajski SR, Shen B (2010) Engineering of Streptomyces platensis MA7339 for overproduction of platencin and congeners. Org Lett 12:1744–1747
Zhang C, Ondeyka J, Herath K, Jayasuriya H, Guan Z, Zink DL, Dietrich L, Burgess B, Ha SN, Wang J, Singh SB (2011) Platensimycin and platencin congeners from Streptomyces platensis. J Nat Prod 74:329–340
Acknowledgments
This work is supported in part by a startup fund from Central South University (CSU) 165000001 (to Y.D. and Y.H.), the Chinese Ministry of Education 111 Project B0803420 (to Y.D.), National High Technology Joint Research Program of China Grant 2011ZX09401-001 (to Y.D.), and US National Institutes of Health Grants GM 114353 (to B.S.). We are grateful to Dr. Lin Qiu and the Center for Advanced Research in CSU in assisting to acquire the 1H NMR of platensimycin.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
This article does not contain any studies with human participants or animals performed by any of the authors.
Conflict of interest
All authors have declared that they have no conflict of interest.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Shi, J., Pan, J., Liu, L. et al. Titer improvement and pilot-scale production of platensimycin from Streptomyces platensis SB12026. J Ind Microbiol Biotechnol 43, 1027–1035 (2016). https://doi.org/10.1007/s10295-016-1769-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10295-016-1769-z